These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19455428)

  • 1. An investigation into the importance of "very rapid dissolution" criteria for drug bioequivalence demonstration using gastrointestinal simulation technology.
    Kovacevi I; Parojci J; Tubi-Grozdanis M; Langguth P
    AAPS J; 2009 Jun; 11(2):381-4. PubMed ID: 19455428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
    Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
    Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
    Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
    J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
    Tsume Y; Amidon GL
    Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
    Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
    Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
    J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help.
    Wu F; Cristofoletti R; Zhao L; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2021 Apr; 42(4):118-127. PubMed ID: 33759204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theoretical Investigation of Dissolution Test Criteria for Waiver of Clinical Bioequivalence Study.
    Sugano K
    J Pharm Sci; 2016 Jun; 105(6):1947-1951. PubMed ID: 27238491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
    Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
    Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets.
    Garcia-Arieta A; Gordon J; Gwaza L; Mangas-Sanjuan V; Álvarez C; Torrado JJ
    Mol Pharm; 2015 Sep; 12(9):3194-201. PubMed ID: 26237401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
    Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
    J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen.
    Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
    J Pharm Sci; 2012 Oct; 101(10):3593-603. PubMed ID: 22786667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study.
    Homsek I; Parojcić J; Dacević M; Petrović L; Jovanović D
    Arzneimittelforschung; 2010; 60(9):553-9. PubMed ID: 21117498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.
    Charoo NA; Cristofoletti R; Dressman JB
    J Pharm Pharmacol; 2015 Aug; 67(8):1156-69. PubMed ID: 25828546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Isavuconazonium Sulfate.
    Plano D; Rudolph N; Saal C; Abrahamsson B; Cristofoletti R; Kambayashi A; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Charoo N; Dressman J
    J Pharm Sci; 2024 Feb; 113(2):386-395. PubMed ID: 37951471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the full potential of the biopharmaceutics classification system reached?
    Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
    Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.